18-06-2025
Positive Report for Cochlear (CHEOF) from UBS
Cochlear (CHEOF – Research Report) received a Buy rating and a A$325.00 price target from UBS analyst Laura Sutcliffe today. The company's shares closed yesterday at $181.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Sutcliffe is a 4-star analyst with an average return of 6.4% and a 56.72% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals, and Cochlear .
In addition to UBS, Cochlear also received a Buy from Jefferies's David Stanton in a report issued on June 13. However, today, Morgans maintained a Hold rating on Cochlear (Other OTC: CHEOF).
Based on Cochlear 's latest earnings release for the quarter ending December 30, the company reported a quarterly revenue of $1.17 billion and a net profit of $205.1 million. In comparison, last year the company earned a revenue of $1.11 billion and had a net profit of $191.4 million
